Overview
This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.
Eligibility
Inclusion Criteria:
- Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy
- Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically
Exclusion Criteria:
- Patients with co-existing malignancies of other organs (or a prior history of such)
- Patients unable to provide informed consent
- Patients unable to complete follow-up


